SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 23, 2004
BioMarin Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 000-26727 | 68-0397820 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) | (IRS Employer Identification No.) |
| 105 Digital Drive, Novato, California | 94949 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (415) 506-6700
371 Bel Marin Keys Boulevard, Suite 210, Novato, California
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
On November 23, 2004, BioMarin Pharmaceutical Inc. (the “Company”) issued a press release regarding the establishment of a strategic relationship with Daiichi Suntory Pharma Co., Ltd. related to the Company’s product candidate Phenoptin. The Company’s press release issued on November 23, 2004 is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements, Pro Forma Financial Statements and Exhibits.
| (a) | Financial Statements of Business Acquired. | |
| Not Applicable. | ||
| (b) | Pro Forma Financial Information. | |
| Not Applicable. | ||
| (c) | Exhibits. | |
| Exhibit 99.1 Press Release of the Company dated November 23, 2004. | ||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BioMarin Pharmaceutical Inc., a Delaware corporation | ||||
| Date: November 24, 2004 | By: | /s/ Jeffrey H. Cooper Jeffrey H. Cooper Chief Financial Officer | ||
EXHIBIT INDEX
| Exhibit No. |
Description | |
| Exhibit 99.1 | Press Release of the Company dated November 23, 2004. |